Pfizer Inc. (PFE) released detailed Phase 3 results Wednesday that should give patients with a certain type of breast cancer some genuine hope. The HER2CLIMB-05 trial tested Tukysa (tucatinib) as a maintenance therapy after chemotherapy in patients with HER2-positive metastatic breast cancer, and the numbers look pretty compelling.

Here's what matters: patients who received Tukysa combined with trastuzumab and pertuzumab saw a 35.9% reduction in their risk of disease progression or death compared to those who got placebo plus the same two companion drugs. That's the kind of statistic that translates to real-world impact.

The median progression-free survival tells the story even more clearly. Patients on the Tukysa regimen went 24.9 months before their disease progressed, versus just 16.3 months for the placebo group. That's an extra 8.6 months where the cancer stayed at bay, which is substantial in the metastatic breast cancer context.

The findings appeared in the Journal of Clinical Oncology and were presented at the San Antonio Breast Cancer Symposium, so this is peer-reviewed data getting attention from the oncology community.

Importantly, the progression-free survival benefit showed up across all prespecified patient subgroups, suggesting the treatment works broadly rather than just for a narrow subset of patients. Overall survival data wasn't mature yet at the time of analysis, but there was a numerical trend favoring Tukysa, which could become more significant with longer follow-up.

On the safety front, the Tukysa combination was generally consistent with what doctors already know about these individual therapies. The main exception: higher rates of asymptomatic Grade 3 or greater liver enzyme elevations. The good news is these were typically manageable and reversible when doctors adjusted Tukysa doses or discontinued treatment temporarily.

Pfizer stock traded up 0.93% to $25.57 following the announcement.